INTRODUCTION
============

Addiction is a chronic disorder in which contextual memories play important roles in drug-taking and drug-seeking ([@B24]). These contextual memories associate specific environments/stimuli with the reinforcing properties of drugs. The hippocampus is likely involved in these responses because of its role in forming context-specific memories that are associated with conditioned responses that boost drug-seeking ([@B30]; [@B24]). In the case of psychostimulant exposure, repeated administration of either cocaine or amphetamine results in enhanced psychomotor responses that are a form of implicit memory called sensitization. Sensitization is not linked to contextual associations; rather, sensitization is linked to plasticity in the dopaminergic signaling in the circuits of the ventral tegmental area, nucleus accumbens, and dorsal striatum ([@B37]; [@B6]). Understanding how these memories (either contextual or implicit) lead to addicted phenotypes might help to address the problem of preventing the reinstatement of drug-seeking, which is a core problem for addiction therapeutics.

One of the neuroplasticity mechanisms by which habit-forming drugs may lead to addiction is the substitution and incorporation of new neurons and glial cells into reward and memory circuits. The brain retains the ability to continuously generate new cells from progenitors that are located in two main proliferative areas, the subventricular zone (SVZ) of the lateral ventricle and the subgranular zone (SGZ) in the dentate gyrus (DG) of the hippocampus ([@B17]; [@B42]). Additional proliferative responses that are associated with the generation of glial cells have been described in the cortex, particularly in the medial prefrontal cortex ([@B26]). While the cells generated in the SVZ primarily migrate to the olfactory bulb, some of the migrating cells progress to adjacent areas that include the striatal complex. SGZ cells differentiate, remain in the hippocampal formation, and are thought to be essential for the remodeling of memories associated with biographic events ([@B42]).

In recent years, compelling evidence has demonstrated that alterations in the rate of cell proliferation in the adult hippocampus may regulate drug-seeking and drug-taking. This phenomenon has been demonstrated for cocaine ([@B11]; [@B34]), amphetamines ([@B27]; [@B38]), alcohol ([@B19]; [@B18]), nicotine ([@B41]), cannabinoids ([@B40]; [@B22]), and opiates ([@B12]). Although in some cases (mostly depending on the dose delivered), drugs of abuse enhance neurogenesis \[see for instance ([@B22])\], these studies have shown that drugs of abuse decrease adult cell proliferation/neurogenesis. The resulting reduction in neuronal turnover sustains drug-seeking by preserving contextual memories associated with drug reward ([@B26]). In the case of cocaine, neurogenesis has been linked to the protection of cocaine-primed relapse ([@B8]), and to the facilitation of the extinction of cocaine-induced place preference ([@B32]), whereas the impairment of neurogenesis increases behavioral sensitization in a rat model ([@B13]), facilitates cocaine self-administration by extending the time required for the extinction of this behavior ([@B34]) and generates deficits in working memory ([@B43]). Moreover, some of these effects are reversed after cocaine withdrawal ([@B35]).

One molecular mechanism that controls cell proliferation in the adult brain, particularly in the hippocampus, is mediated by the endogenous cannabinoid system. This lipid signaling system not only regulates embryonic cell fate in the developing brain but also regulates adult neurogenesis ([@B1]; [@B15]; [@B10]). This effect is mediated through the activations of CB~1~ and CB~2~ receptors ([@B23]; [@B21]). The effects of the endogenous cannabinoid system can be bidirectional; i.e., the endogenous cannabinoid system can promote cell proliferation during development or after brain insult ([@B1], [@B2]) or reduce cell proliferation when overstimulated by the administration of cannabinoids ([@B40]; [@B20]). The contribution of the endogenous cannabinoid system to cocaine-induced alterations in neurogenesis is not known. However, there is clear evidence that both CB~1~ and CB~2~ receptors are linked to the generation of contextual memories associated with cocaine-induced sensitization and cocaine seeking and relapse ([@B16]; [@B9]; [@B14]; [@B3]). To further explore the role of the endogenous cannabinoid system in regulating memories associated with cocaine exposure, the present study examined whether the blockade of either CB~1~ or CB~2~ cannabinoid receptors during repeated administration of cocaine is capable of (a) affecting the acquisition of cocaine-induced sensitization, (b) disrupting the appearance of cocaine-induced conditioned locomotion, or (c) modulating cocaine-induced cell proliferation.

MATERIALS AND METHODS {#s1}
=====================

ANIMALS
-------

All experimental animal procedures were performed in compliance with the European Directive 2010/63/EU on the protection of animals used for scientific purposes and with Spanish regulations (RD 53/2013 and 178/2004). Male Wistar rats (approximately 250 g, 10--12 weeks old; Charles Rivers, Barcelona, Spain) were housed in groups of two in cages maintained in standard conditions (Servicio de Estabulario, Facultad de Medicina, Universidad de Málaga) at room temperature (20°± 2°C), 40 ± 5% relative humidity and a 12-h light/dark cycle with a dawn/dusk effect.

DRUG ADMINISTRATION
-------------------

Cocaine hydrochloride was obtained from the Alcaliber Company (Toledo, Spain), subsequent to receiving authorization from the Spanish Agency of Medicines and Medical Devices and dissolved in a sterile 0.9% NaCl solution immediately prior to experimentation. Rats were given acute (20 mg/kg) injections, repeated injections (20 mg/kg) and/or an acute challenge injection (priming, 10 mg/kg) of cocaine. Both Rimonabant and AM630 were dissolved in 1% Tween 80 and a sterile 0.9% NaCl solution and administered at a dose of 3 mg/kg. The drugs were injected intraperitoneally (i.p.) in final volumes of 1 ml/kg.

BrdU ADMINISTRATION
-------------------

Doses of 50 mg/kg of 5-bromo-2′-deoxyuridine (BrdU, cat. no. B5002, Sigma, St. Louis, MO, USA) were dissolved at 15 mg/mL in a 0.9% saline solution and administered i.p. three times prior to, immediately after and 8 h after the single (acute group) or the final (repeated cocaine injection groups) cocaine doses.

BEHAVIORAL STUDIES
------------------

### Open field test

Four open field (OF) mazes with gray backgrounds and dimensions (in cm) of L50 × W50 × H50 were used (Panlab, Barcelona, Spain). The arenas were uniformly illuminated by a fluorescent lamp, and the light intensities at the centers of the arenas were 50--70 lx. All behavioral procedures were carried out between 8:00 a.m. and 6:00 p.m. The animals were placed individually in the center of each arena after treatments, and their behaviors were recorded and analyzed for 20 min with a video tracking system (Smart®, Panlab, Barcelona, Spain). The apparatus was cleaned between sessions with 70% ethanol and then dried. Locomotor activity was assessed by measuring the total distance traveled (in cm) by each rat. The testing orders of the groups and the treatments were counterbalanced in all behavioral experiments to avoid confounding effects of the time of the day at which the animals were tested.

### Handling and acclimation

The animals were weighed, handled (10 min) and habituated daily to the injection procedures (i.e., they were held and pseudo-injected) over 1 week to minimize stress effects. For the pseudo-injection, the lower abdomen of the rat was pressed with a capped syringe. Before beginning the experiment each day, the animals were acclimated to the testing room for 20 min.

### Locomotor activity after acute and repeated administration of cocaine and co-administration of cocaine and rimonabant or AM630

One group of animals received a vehicle injection, and these animals were immediately placed in the OF for 20 min to measure spontaneous locomotor activity. Twenty-four hours later, the animals were re-exposed to the OF for 20 min to assess the effects of the administration of vehicle or the acute administration of cocaine (20 mg/kg). The animals also received BrdU as described above (**Figure [1](#F1){ref-type="fig"}**). This group of animals (i.e., the vehicle-injected and cocaine-exposed group) was sacrificed and perfused 6 days after cocaine injection. A separate group of animals was used to assess locomotion responses after co-administration of cocaine with either vehicle, Rimonabant or AM630. The experimental groups that were monitored after acute co-administration of treatments were as follows (*n* = 8/group): vehicle, Rimonabant (3 mg/kg), AM630 (3 mg/kg), cocaine (20 mg/kg), Rimonabant (3 mg/kg) + cocaine (20 mg/kg), and AM630 (3 mg/kg) + cocaine (20 mg/kg). An independent group of animals of the same size and treatment distribution was also tested in the OF for 20 min after the injection of vehicle injection (day 1); over the following 4 days (days 2--5), these animals received repeated administrations of vehicle, Rimonabant, AM630, or cocaine or repeated co-administration of cocaine and Rimonabant or AM630 as described above (*n* = 8/group; **Figure [1](#F1){ref-type="fig"}**). On the final day of cocaine administration, BrdU was also administered.

![**Schematic representation of the treatments and the behavioral protocols used in this study.** The locomotor activities of two independent groups of rats were evaluated in the OF after acute and repeated administration of cocaine and co-administration of cocaine (20 mg/kg) and Rimonabant (3 mg/kg) or AM630 (3 mg/kg). Conditioned locomotion responses (5 days after last cocaine injection) and cocaine-induced sensitization with priming doses of cocaine (10 mg/kg) were evaluated. After treatments, all animals were tested daily in the OF, and locomotion was measured for 20 min. Three doses of BrdU were administered to each animal prior to, immediately after and 8 h after the last cocaine injection for the analyses of brain cell proliferation.](fnint-07-00106-g001){#F1}

### Cocaine-induced conditioned locomotion and sensitization

After the repeated treatments were completed, the animals were left undisturbed in their home cages from day 5 to day 9 (resting period). On the 10th day, we assessed conditioned locomotion responses and the locomotor activity responses induced by the contextual memories formed through the association of the repeated administrations of cocaine and the place in which the cocaine exerted its stimulant effects. To this end, the animals were injected with vehicle and placed in the OF, and their locomotions were recorded for 10 min. On the following day (day 11), we tested the rats' responses to a single dose of cocaine (a lower priming dose of cocaine, 10 mg/kg) in the OF context that had previously been associated with cocaine administration (**Figure [1](#F1){ref-type="fig"}**). The cocaine-induced sensitization responses of the animals were evaluated for 30 min in the OF test.

SAMPLE COLLECTION
-----------------

The following seven experimental groups (*n* = 8/group) were processed for histology: vehicle, acute cocaine, repeated cocaine, Rimonabant, AM630, repeated cocaine + Rimonabant and repeated cocaine + AM630. The animals were anesthetized (sodium pentobarbital, 50 mg/kg, i.p.) 1 h after the final administration of vehicle or cocaine in a room that as isolated from the other experimental animals. The animals were then transcardially perfused with 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS), and their brains were dissected and maintained in the same fixative solution overnight at 4°C. The brains were then cut into 40-μm-thick coronal sections and divided into five parallel series using a vibratome (Leica VT1000S). The sections were stored at 4°C in PB with 0.002% (w/v) sodium azide until further use for immunohistochemistry.

BrdU IMMUNOHISTOCHEMISTRY
-------------------------

To analyze cell proliferation in the SVZ of the lateral ventricles and the SGZ of DG, free-floating coronal sections from 2.28 to -0.24 and from -2.16 to -4.20 relative to bregma ([@B36]) were selected from one of the five parallel series obtained from each brain of the rats in the seven experimental groups. The sections were first washed several times with PBS to remove the sodium azide and then incubated in a solution of 3% hydrogen peroxide and 10% methanol in 0.1 M PB for 45 min at room temperature in darkness to inactivate the endogenous peroxidase. After three washes in PBS for 10 min, the DNA was denatured by exposing the sections to 2 M HCl for 15 min at 37°C, and this process was followed by two washes in 0.15 M borate buffer to neutralize the pH. After three 10 min washes in PBS, the sections were incubated in a blocking solution containing 0.3% albumin, 0.3% triton X-100, and 0.05% sodium azide in PBS for 45 min. The sections were then incubated overnight in mouse anti-BrdU (1:2000, Hybridoma Bank, Iowa City, IA, USA; ref. G3G4) at 4°C ([@B7]; [@B39]). The following day, the sections were washed three times with PBS, incubated in biotinylated goat anti-mouse immunoglobulin G (IgG; H + L; 1:1000, Pierce, Rockford, IL, USA; cat. no. 31800) for 90 min, washed again in PBS and incubated in avidin--biotin peroxidase complex (Pierce) diluted 1:250 in PBS in darkness at room temperature for 45 min. After three washes in PBS in darkness, immunolabeling was revealed with 0.05% diaminobenzidine (DAB; Sigma), 0.05% nickel ammonium sulfate and 0.03% H~2~O~2~ in PBS. After several washes in PBS, the sections were mounted in slides treated with poly-l-lysine solution (Sigma), air-dried, dehydrated in ethanol, cleared with xylene and coverslipped with Eukitt mounting medium (Kindler GmBH & Co, Freiburg, Germany). Digital high-resolution photomicrographs of the rat brains were taken under constant light, brightness and contrast conditions with an Olympus BX41 microscope equipped with an Olympus DP70 digital camera (Olympus Europa GmbH, Hamburg, Germany). Representative digital images were mounted and labeled using Microsoft PowerPoint 2007.

CLEAVED Caspase-3, GFAP, AND Iba-1 IMMUNOHISTOCHEMISTRY
-------------------------------------------------------

To analyze the immunohistochemical expression of cleaved caspase-3, glial fibrillary acidic protein (GFAP), and Iba-1 in the striatum and the hippocampus, free-floating coronal sections from 2.28 to -0.24 and from -2.16 to -4.20 relative to bregma levels ([@B36]) were selected from one of five parallel series obtained from each brain of the rats in the seven experimental groups. One immunostaining batch containing 56 slides (seven groups, eight animals each) was stained simultaneously to avoid variations in staining intensity due to the staining procedures. Free-floating sections were first washed several times with PBS to remove the sodium azide and then incubated in sodium citrate (50 mM in dH2O, pH 6) for 30 min at 80°C. This process was followed by three 10 min washes in PBS and incubation in 3% hydrogen peroxide in PBS for 20 min in darkness at room temperature to inactivate endogenous peroxidase. The sections were then incubated in a blocking solution containing 10% serum (donkey or goat), 0.3% triton X-100, and 0.1% sodium azide in PBS for 1 h. The sections were incubated overnight in the following diluted primary antibodies at 4°C: rabbit anti-cleaved caspase-3 (1:500, Cell Signaling; cat. no. 9661), mouse anti-GFAP (1:500, Sigma; cat. no. G3893), or rabbit anti-Iba-1 (1:1000, Wako, Osaka, Japan; cat. no. 019-19741). The following day, the sections were incubated with one of the following secondary antibodies for 1 h as appropriate: biotinylated goat anti-mouse IgG (1:500, Sigma; cat. no. B7264) or biotinylated donkey anti-rabbit IgG (1:500, Amersham, Little Chalfont, England; cat. no. RPN 1004). The sections were then washed three times with PBS and incubated in ExtrAvidin peroxidase (Sigma, St. Louis, MO, USA) diluted 1:2000 in darkness at room temperature for 1 h. After three washes in PBS in darkness, we revealed the immunolabeling with 0.05% DAB (Sigma), 0.05% nickel ammonium sulfate, and 0.03% H2O2 in PBS. The next histological steps were performed as described above. Digital high-resolution photomicrographs of the rat brains were taken using conditions and equipment that were identical to those described above.

QUANTIFICATION OF BrdU, CLEAVED CASPASE-3, GFAP, AND Iba1-IMMUNOREACTIVE CELLS
------------------------------------------------------------------------------

To quantify cell proliferation in the SVZ and SGZ and apoptosis and gliosis in the striatum and the hippocampus, immunoreactive (-ir) nuclei and cells that came into focus were manually counted using a standard optical microscope with a 40 × objective. BrdU-ir nuclei in the SVZ and SGZ and cleaved caspase-3-, GFAP- and Iba1-ir cells of the striatum and hippocampal DG, CA3, and CA1 regions were counted from 2.28 to -0.24 and from -2.16 to -4.20 relative to bregma, respectively ([@B36]); thus, twenty 40-μm thick coronal sections per animal were used. We considered the same numbers of sections per brain region for each analyzed animal. Cell counts were performed in both cerebral hemispheres in all cases. The results are expressed as the average numbers of ir nuclei/cells per section or area (mm^2^) for each of the following experimental group (*n* = 8/group): vehicle, acute cocaine, repeated cocaine, Rimonabant, AM630, repeated cocaine + Rimonabant and repeated cocaine + AM630.

QUANTIFICATION OF GFAP IMMUNOREACTIVITY
---------------------------------------

Digital high-resolution microphotographs of the striatum and hippocampus were taken with a 10 × objective under constant light, brightness and contrast conditions with an Olympus BX41 microscope equipped with an Olympus DP70 digital camera. Densitometric quantifications of the immunoreactivities of representative areas were determined using the ImageJ 1.38X (NIH, MD, USA) analysis software. In each tissue section, we focused on the dorsal striatum, the hippocampal CA1 and CA3 areas of Ammon's horn and the DG. For both CA areas, we considered the following layers: stratum oriens (SO), stratum pyramidale (SP), stratum radiatum (SR), stratum lucidum (SL), and stratum lacunosum-moleculare (SL-M). For the DG, we considered following layers; the molecular layer (ml), the granular cell layer (gcl) and the polymorphic cell layer (pcl).

STATISTICAL ANALYSIS
--------------------

The data are represented as the mean ± the SEM from at least eight animals. Kolmogorov--Smirnov normality tests indicated that all data followed Gaussian distributions (*P* \> 0.1); thus, parametric statistical tests were selected. Statistical analyses of the histological data were performed with one-way ANOVA. Behavioral data were analyzed with one- or two-way repeated measures ANOVA with the factors of time (days) and treatment (vehicle, Rimonabant, AM630, cocaine, Rimonabant + cocaine and AM630 + cocaine) followed by Bonferroni *post hoc* tests for multiple comparisons. *P* values less than 0.05 were considered statistically significant.

RESULTS
=======

EFFECT OF ACUTE AND REPEATED ADMINISTRATION OF COCAINE AND CO-ADMINISTRATION OF COCAINE AND RIMONABANT OR AM630
---------------------------------------------------------------------------------------------------------------

To study the interaction of the pharmacological blockade of CB~1~ and CB~2~ receptors and the acute stimulating effects of cocaine, we evaluated locomotor responses to acute doses of cannabinoid receptor antagonists (Rimonabant or AM630 at 3 mg/kg, i.p.) that were administered alone or in combination with cocaine (20 mg/kg, i.p.; **Figure [2A](#F2){ref-type="fig"}**). All animals received an administration of vehicle on day 1 and the treatment administration 24 h later. A two-way ANOVA revealed that the main effects of group and day and the interaction between group and day were all significant \[*F*(5,42) = 8.39, *P* \< 0.001; *F*(1,42) = 21.71, *P* \< 0.001; *F*(5,42) = 8.36, *P* \< 0.001, respectively\]. *Post hoc* comparisons revealed that the groups that received acute injections cocaine (alone and in combination with Rimonabant or AM630) exhibited similar significant increases in locomotion (**Figure [2A](#F2){ref-type="fig"}**). Moreover, *post hoc* analysis indicated that these groups displayed significantly enhanced locomotor activity compared to the groups that received an acute dose of vehicle or CB~1~ and CB~2~ antagonists during the second exposure to the OF (**Figure [2A](#F2){ref-type="fig"}**). Further *post hoc* comparisons revealed a reduction in locomotion after a single administration of Rimonabant. In general, these results indicate that acute co-administration of CB~1~ and CB~2~ antagonists with cocaine did not affect the acute stimulating effects of cocaine.

![**(A)** Effects of acute administration of cocaine and co-administration of cocaine (20 mg/kg) and Rimonabant (3 mg/kg) or AM630 (3 mg/kg) in the OF test. The acute cocaine-treated groups (cocaine, cocaine + Rimonabant and cocaine + AM630) exhibited significant increases in locomotor activity compared to the previous vehicle administration on day 1 (^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001) and compared to the vehicle group (^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01, ^\#\#\#^*P* \< 0.001). **(B)** The effects of repeated administration of cocaine and co-administration of cocaine (20 mg/kg) and Rimonabant (3 mg/kg) or AM630 (3 mg/kg) in the OF test. The repeated cocaine-treated groups (cocaine, cocaine + Rimonabant and cocaine + AM630) exhibited greater locomotion than did the groups that did not receive cocaine (vehicle, Rimonabant and AM630) on days 2 (^\#^*P* \< 0.05), 3 (^\#\#^*P* \< 0.01), 4 and 5 (^\#\#\#^*P* \< 0.001). The cocaine + Rimonabant group exhibited reduced horizontal locomotion on days 4 and 5 compared to the other repeated cocaine-treated groups (cocaine and cocaine + AM630; ^+^*P* \< 0.05, ^++^*P* \< 0.01). All results are presented as the means ± the SEMs (*n* = 8/group).](fnint-07-00106-g002){#F2}

To determine whether cannabinoid receptor antagonism modulates the acquisition of cocaine conditioning processes in the OF, we assessed the effects of repeated co-administration of CB~1~ and CB~2~ antagonists with cocaine. After an initial day on which all experimental groups received vehicle injection, the animals received repeated administrations of vehicle, Rimonabant, AM630, or cocaine or co-administration of cocaine and Rimonabant or AM630 for four consecutive days (**Figure [2B](#F2){ref-type="fig"}**). A repeated-measures ANOVA revealed that the main effects of treatment \[*F*(5,42) = 52.57, *P* \< 0.001)\], day \[*F*(4,168) = 17.82, *P* \< 0.001\], and the day x treatment interaction \[*F*(20,168) = 7.41, *P* \< 0.001\] were all significant. *Post hoc* comparisons indicated that the three groups that received cocaine (alone or in combination with CB~1~ and CB~2~ antagonists) exhibited significantly increased locomotor activity over all 4 days of cocaine conditioning acquisition relative to the vehicle-, Rimonabant- and AM630-treated groups (no differences between these latter groups were found). However, *post hoc* analyses also revealed that the cocaine + Rimonabant group exhibited reduced horizontal locomotion on days 3 and 4 relative to the other groups that received repeated cocaine injections (i.e., the cocaine and cocaine + AM630 groups; **Figure [2B](#F2){ref-type="fig"}**). These results may indicate that the co-administration of Rimonabant may attenuate the acquisition of cocaine-sensitized responses.

EFFECT OF REPEATED ADMINISTRATION OF COCAINE AND CO-ADMINISTRATION OF COCAINE AND RIMONABANT OR AM630 ON CONDITIONED LOCOMOTION AND SENSITIZATION RESPONSES
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Repeated injections of cocaine-induced a conditioned locomotion response in the cocaine-treated group relative to the vehicle group (*P* \< 0.05). Although the cocaine + Rimonabant and cocaine + AM630 groups were repeatedly injected with cocaine, only the cocaine-treated group exhibited a normal conditioned locomotor response (**Figure [3A](#F3){ref-type="fig"}**). The attenuated expression of conditioned locomotion in the cocaine + Rimonabant group may have been due to weaker acquisition of cocaine conditioning (days 3--4; **Figure [2B](#F2){ref-type="fig"}**).

![**(A)** Effects of repeated administration of cocaine and co-administration of cocaine (20 mg/kg) and Rimonabant (3 mg/kg) or AM630 (3 mg/kg) on the conditioned locomotion response measured in the OF test. Five days after the final cocaine injection, only the cocaine-treated group exhibited elevated conditioned locomotion responses compared to the vehicle group (^\*^*P* \< 0.05) after a vehicle injection. **(B)** Effects of repeated administration of cocaine and co-administration of cocaine (20 mg/kg) and Rimonabant (3 mg/kg) or AM630 (3 mg/kg) on cocaine-induced sensitization measured in the OF test. The repeated cocaine-treated groups (cocaine, cocaine + Rimonabant and cocaine + AM630) exhibited significantly enhanced cocaine-sensitized responses after receiving an acute challenge injection (priming, 10 mg/kg) compared to the groups that did not receive cocaine (vehicle, Rimonabant and AM630; ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01). All results are presented as the means ± the SEMs (*n* = 8/group).](fnint-07-00106-g003){#F3}

On the following day, we measured cocaine-induced sensitization with an acute challenge injection of cocaine (priming, 10 mg/kg). A one-way ANOVA revealed that the main effect of group was significant \[*F*(5,45) = 5.17, *P* \< 0.001\]. Our results revealed that the groups that received repeated cocaine injections (20 mg/kg) alone or in combination with CB~1~ and CB~2~ antagonists (i.e., the cocaine + Rimonabant and cocaine + AM630 groups) exhibited significantly increased locomotor activity compared to their control groups (*P* \< 0.05 and 0.01, respectively; **Figure [3B](#F3){ref-type="fig"}**) as a result of cocaine-induced sensitization. In brief, cannabinoid receptor antagonism (with Rimonabant or AM630) did not affect the expression of cocaine-induced sensitization.

EFFECT OF ACUTE AND REPEATED ADMINISTRATION OF COCAINE AND CO-ADMINISTRATION OF COCAINE WITH RIMONABANT OR AM630 ON NEWBORN CELLS IN RELEVANT NEUROGENIC ZONES
--------------------------------------------------------------------------------------------------------------------------------------------------------------

To investigate the effects of acute and repeated cocaine administration and co-administration of cocaine with the CB~1~ and CB~2~ antagonists Rimonabant and AM630 on cell proliferation in the relevant neurogenic zones, we evaluated newborn cells in the SVZ and SGZ via analyses of BrdU labeling (50 mg/kg; (**Figure [4](#F4){ref-type="fig"}**). Both the acute and repeated cocaine-treated rats exhibited lower numbers of BrdU-ir cells in the SVZ compared to the vehicle-treated rats (^\*\*\*^*P* \< 0.001; **Figures [4A,C--E](#F4){ref-type="fig"}**). Interestingly, the numbers of BrdU-ir cells were significantly lower in the SVZs of the acute compared to the repeated cocaine-treated rats (^\$\$\$^*P* \< 0.001). Moreover, both AM630 and Rimonabant also produced significant reductions in the numbers of BrdU-ir cells of the SVZ compared to vehicle (^\*\*^*P* \< 0.01 and ^\*\*\*^*P* \< 0.001, respectively; **Figures [4A,F,H](#F4){ref-type="fig"}**). Repeated AM630 or Rimonabant co-administration with cocaine resulted in further significant reductions in the numbers of BrdU-ir cells observed in the SVZs of the repeated cocaine-treated rats (^\$\$^*P* \< 0.01; **Figures [4A,G,I](#F4){ref-type="fig"}**).

![**Effects of repeated administration of cocaine and co-administration of cocaine (20 mg/kg) and Rimonabant (3 mg/kg) or AM630 (3 mg/kg) on cell proliferation in the SVZ (A) and the SGZ (B) as measured with BrdU immunohistochemistry.** Repeated AM630 or Rimonabant administration increased the numbers of BrdU-ir cells observed in the SVZ and SGZ of the repeated cocaine-treated rats. **(C--P)** Representative microphotographs showing low- and high-magnification (insets) views of the typical clusterings of newborn cells in the subventricular zone of the lateral ventricle and the inner border of the granular cell layer. The histogram displays the means ± SEMs (*n* = 8/group) of the numbers of BrdU-ir nuclei per area (mm^2^). One-way ANOVA: ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001 vs. vehicle group; ^\$\$^*P* \< 0.01, ^\$\$\$^*P* \< 0.001 vs. repeated cocaine group; ^\#\#\#^*P* \< 0.001 vs. Rimonabant group. Scale bars are included in each image.](fnint-07-00106-g004){#F4}

Lower numbers of BrdU-ir cells were observed in the SGZs of the acute cocaine-treated rats than in the vehicle-treated rats (^\*^*P* \< 0.05) or the repeated cocaine-treated rats (^\$\$\$^*P* \< 0.001; **Figures [4B,J--L](#F4){ref-type="fig"}**). Thus, no differences in the numbers of BrdU-ir cells were found in the SGZs of the repeated cocaine-treated rats compared to the vehicle rats. In contrast, both AM630 and Rimonabant induced increases in the numbers of BrdU-ir cells in the SGZ compared to vehicle (^\*\*^*P* \< 0.01 and ^\*^*P* \< 0.05, respectively; **Figures [4B,M,O](#F4){ref-type="fig"}**). The increases in the numbers of BrdU-ir cells after repeated AM630 or Rimonabant administration were maintained (^\$\$^*P* \< 0.01) and increased (^\$\$\$^*P* \< 0.001), respectively, in the SGZs of repeated cocaine-treated rats (**Figures [4B,N,P](#F4){ref-type="fig"}**).

EFFECT OF ACUTE AND REPEATED ADMINISTRATION AND CO-ADMINISTRATION OF COCAINE WITH RIMONABANT OR AM630 ON APOPTOTIC CELLS IN THE STRIATUM AND THE HIPPOCAMPUS
------------------------------------------------------------------------------------------------------------------------------------------------------------

Apoptotic cells, as determined by cleaved caspase-3 immunostaining, were assessed in the striata and the hippocampal DG, CA1, and CA3 areas of rats that were administered acute or repeated cocaine with in combination with the CB~1~ and CB~2~ antagonists Rimonabant and AM630, respectively (**Figure [5](#F5){ref-type="fig"}**). No differences in the numbers of cleaved caspase 3-ir cells were detected in the striata of the acute or repeated cocaine-treated rats compared to the vehicle-treated rats (**Figures [5A,C--E](#F5){ref-type="fig"}**). Rimonabant, but not AM630, produced a small but significant reduction in the number of cleaved caspase 3-ir cells in the striatum (^\*^*P* \< 0.05; **Figures [5A,F,H](#F5){ref-type="fig"}**). This reduction in the number of cleaved caspase 3-ir cells in the striatum was also present after the co-administration of cocaine and Rimonabant compared to the vehicle- or repeated cocaine-treated rats (^\*^*P* \< 0.05, ^\$^*P* \< 0.05; **Figures [5A,G,I](#F5){ref-type="fig"}**).

![**Effects of repeated administration of cocaine and co-administration of cocaine (20 mg/kg) and Rimonabant (3 mg/kg) or AM630 (3 mg/kg) on cell apoptosis in the striatum (A) and hippocampus (B) as measured with cleaved caspase-3 immunohistochemistry.** Rimonabant administration decreased the numbers of cleaved caspase 3-ir cells observed in the striata and hippocampi of the repeated cocaine-treated rats. Only AM630 decreased the numbers of cleaved caspase 3-ir cells in the hippocampi of the repeated cocaine-treated rats. **(C--P)** Representative microphotographs showing low- and high-magnification (insets) views of apoptotic cells in the striatum and hippocampus. The histogram displays the means ± SEMs (*n* = 8/group) of the numbers of cleaved caspase 3-ir cells per area (mm^2^). One-way ANOVA: ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001 vs. vehicle group; ^\$^*P* \< 0.05, ^\$\$^*P* \< 0.01 vs. repeated cocaine group; ^\#\#^*P* \< 0.01, ^\#\#\#^*P* \< 0.001 vs. Rimonabant group. Scale bars are included in each image.](fnint-07-00106-g005){#F5}

Increased numbers of cleaved caspase 3-ir cells were observed in the hippocampi of both acute and repeated cocaine-treated rats (^\*\*\*^*P* \< 0.001; **Figures [5B,J--L](#F5){ref-type="fig"}**). Regarding the three hippocampal areas analyzed (i.e., the DG, CA1, and CA3), increased numbers of cleaved caspase 3-ir cells were found in the DG and CA1 areas of both the acute and repeated cocaine groups (^\*\*\*^*P* \< 0.001 and ^\*\*^*P* \< 0.01, respectively) and in the CA3 area of the acute cocaine group (^\*\*^*P* \< 0.01). In contrast, no increase was detected in the CA3 areas of the repeated cocaine-treated rats (**Figures [5B,J--L](#F5){ref-type="fig"}**). AM630 but not Rimonabant produced a small increase in the number of cleaved caspase 3-ir cells in the hippocampus (^\*^*P* \< 0.05), and this result was the a consequence of the prominent increase in the number of cleaved caspase 3-ir cells that was specifically observed in the DG (^\*\*\*^*P* \< 0.001) and not in the CA1 and CA3 fields (**Figures [5B,M,O](#F5){ref-type="fig"}**). Interestingly, we observed decreases in the numbers of hippocampal cleaved caspase 3-ir cells after repeated AM630 or Rimonabant administration in the repeated cocaine-treated rats (^\$^*P* \< 0.05 and ^\$\$^*P* \< 0.01, respectively; **Figures [5B,N,P](#F5){ref-type="fig"}**).

EFFECTS OF ACUTE AND REPEATED ADMINISTRATION OF COCAINE AND CO-ADMINISTRATION OF COCAINE WITH RIMONABANT or AM630 ON ASTROGLIOSIS IN THE STRIATUM AND THE HIPPOCAMPUS
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

To investigate the effects of acute and repeated cocaine administration and the co-administration of the CB~1~ and CB~2~ antagonists Rimonabant and AM630 on astrogliosis, we evaluated the intensities of GFAP immunoreactivity and the numbers of astrocytes expressing GFAP in the striatum and the hippocampal DG, CA1, and CA3 areas (**Figure [6](#F6){ref-type="fig"}**). A greater number of GFAP-ir cells were observed in the striatum of the acute cocaine-treated rats compared to the vehicle-treated (^\*\*^*P* \< 0.01) and repeated cocaine-treated rats (^\$\$\$^*P* \< 0.001; **Figures [6A,E--G](#F6){ref-type="fig"}**). Thus, no differences in the numbers of GFAP-ir cells were observed in the striata of the repeated cocaine-treated rats compared to the vehicle-treat rats. Moreover, the striata of the rats treated with AM630 or Rimonabant did not exhibit differences in the numbers of GFAP-ir cells when compared to the vehicle group (**Figures [6A,H,J](#F6){ref-type="fig"}**). A specific decrease in the numbers of GFAP-ir cells was observed in the striata of the repeated cocaine-treated rats that were co-administered AM630 (^\$^*P* \< 0.05) but not Rimonabant (**Figures [6A,I,K](#F6){ref-type="fig"}**). Analyses of GFAP immunoreactivity intensities in the striatum (**Figure [6B](#F6){ref-type="fig"}**) revealed no differences between the vehicle-, acute cocaine- and repeated Rimonabant groups (**Figures [6B,E,F,J](#F6){ref-type="fig"}**). In contrast, decreases in GFAP immunostaining were detected in the striata of the repeated cocaine- and AM630-treated rats (^\*^*P* \< 0.05; **Figures [6B,G,H](#F6){ref-type="fig"}**). No effects of repeated AM630 or Rimonabant treatment on GFAP expression were observed in the striata of the repeated cocaine-treated rats (**Figures [6B,I,K](#F6){ref-type="fig"}**).

![**Effects of repeated administration of cocaine and co-administration of cocaine (20 mg/kg) and Rimonabant (3 mg/kg) or AM630 (3 mg/kg) on astrogliosis in the striatum (A,B) and the hippocampus (C,D) as measured with GFAP immunohistochemistry.** AM630 administration decreased the numbers of GFAP-ir cells observed in the striata of the repeated cocaine-treated rats. Both AM630 and Rimonabant induced decreases in the numbers of GFAP 3-ir cells and reduced the intensities of GFAP immunoreactivity in the hippocampi of the repeated cocaine-treated rats. **(E--R)** Representative microphotographs showing low- and high-magnification (insets) views of astroglial cells in the striatum and hippocampus. The histogram displays the means ± the SEMs (*n* = 8/group) of the numbers of GFAP-ir cells per area (mm^2^) and GFAP immunoreactivities (arbitrary units). One-way ANOVA: ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001 vs. vehicle group; ^\$^*P* \< 0.05, ^\$\$^*P* \< 0.01, ^\$\$\$^*P* \< 0.001 vs. repeated cocaine group; ^&^*P* \< 0.05, ^&&^*P* \< 0.01 vs. AM630 group; ^\#\#^*P* \< 0.01, ^\#\#\#^*P* \< 0.001 vs. Rimonabant group. Scale bars are included in each image.](fnint-07-00106-g006){#F6}

Greater numbers of GFAP-ir cells were observed in the hippocampi of the acute and repeated cocaine-treated rats and the AM630 and Rimonabant-treated rats compared to the vehicle-treated rats (^\*\*\*^*P* \< 0.001; **Figures [6C,L--N,O,Q](#F6){ref-type="fig"}**). These effects were accompanied by different levels of significance across the three analyzed regions of the hippocampus (i.e., the DG, CA1, and CA3). Notably, the increase in the number of GFAP-ir cells was significantly greater in the hippocampi of the acute cocaine group than in the hippocampi of the remaining groups including the repeated cocaine group (^\$\$^*P* \< 0.01). Specifically, this difference in GFAP-ir cell numbers between the acute and repeated cocaine groups was observed in the CA1 and CA3 fields (^\$\$\$^*P* \< 0.001) and not in the DG. The hippocampi of the repeated cocaine-treated rats that also received repeated AM630 or Rimonabant exhibited decreases in the numbers of GFAP-ir cells (^\$\$^*P* \< 0.01), particularly in the DG (^\$\$\$^*P* \< 0.001 and ^\$\$^*P* \< 0.01 for the AM630 and Rimonabant co-administration groups, respectively) and not in the CA3 field (**Figures [6C,P,R](#F6){ref-type="fig"}**). Analyses of GFAP immunoreactivity intensities in the hippocampus (**Figure [6D](#F6){ref-type="fig"}**) revealed more intense immunostaining in the acute and repeated cocaine-treated rats compared to the vehicle-treated rats (^\*\*\*^*P* \< 0.001; **Figures [6D,L--N](#F6){ref-type="fig"}**). Across all hippocampal regions analyzed (i.e., DG, CA1, and CA3), GFAP immunoreactivity was more intense in the acute cocaine-treated rats than in the repeated cocaine-treated rats (^\$\$^*P* \< 0.01). Notably, no effects of pharmacological blockade of CB~1~ or CB~2~ receptors on GFAP immunoreactivities were observed when the total hippocampi were analyzed (**Figures [6D,O,Q](#F6){ref-type="fig"}**). However, decreases in GFAP immunostaining were specifically observed in the CA3 fields of rats that were administered AM630 (^\*\*^*P* \< 0.01) or Rimonabant (^\*^*P* \< 0.05) compared to the vehicle group. Moreover, repeated administrations of AM630 or Rimonabant induced decreases in GFAP immunostaining in the hippocampi of the repeated cocaine-treated rats (**Figures [6D,P,R](#F6){ref-type="fig"}**).

EFFECTS OF ACUTE AND REPEATED ADMINISTRATION OF COCAINE AND CO-ADMINISTRATION OF COCAINE WITH RIMONABANT OR AM630 ON MICROGLIOSIS IN THE STRIATUM AND THE HIPPOCAMPUS
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

To investigate the effects of the acute and repeated cocaine administration and co-administration with the CB~1~ and CB~2~ antagonists Rimonabant and AM630 on microgliosis, we evaluated the numbers of cells that expressed Iba1 in the striatum and the hippocampal DG, CA1, and CA3 areas (**Figure [7](#F7){ref-type="fig"}**). No differences in the numbers of Iba-ir cells were observed in the striata of the acute or repeated cocaine-treated rats or the AM630- or Rimonabant-treated rats compared to the vehicle-treated rats (**Figures [7A,C--F,H](#F7){ref-type="fig"}**). However, the numbers of Iba1-ir cells were higher in the striata of the acute cocaine-treated rats than in the repeated cocaine-treated rats (^\$^*P* \< 0.05; **Figures [7A,C--E](#F7){ref-type="fig"}**). Interestingly, we observed decreases in the numbers of striatal Iba1-ir cells after repeated AM630 or Rimonabant administration in the repeated cocaine-treated rats (^\$\$\$^*P* \< 0.001 and ^\$\$^*P* \< 0.01, respectively; **Figures [7A,G,I](#F7){ref-type="fig"}**).

![**Effects of repeated administration of cocaine and co-administration of cocaine (20 mg/kg) and Rimonabant (3 mg/kg) or AM630 (3 mg/kg) on microgliosis in the striatum (A)** and the hippocampus **(B)** as measured with Iba-1 immunohistochemistry. AM630 and Rimonabant administration decreased the numbers of Iba1-ir cells observed in the striata but not the hippocampi of the repeated cocaine-treated rats. **(C--P)** Representative microphotographs showing low- and high-magnification (insets) views of microglial cells in the striatum and hippocampus. The histogram displays the means ± the SEMs (*n* = 8/group) of the numbers of Iba1-ir cells per area (mm^2^). One-way ANOVA: ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001 vs. vehicle group; ^\$^*P* \< 0.05, ^\$\$^*P* \< 0.01, ^\$\$\$^*P* \< 0.001 vs. repeated cocaine group; ^&&&^*P* \< 0.001 vs. AM630 group; ^\#^*P* \< 0.05 vs. Rimonabant group. Scale bars are included in each image.](fnint-07-00106-g007){#F7}

Increased numbers of Iba1-ir cells were observed in the hippocampi of both the acute and repeated cocaine-treated rats (^\*\*\*^*P* \< 0.001; **Figures [7B,J--L](#F7){ref-type="fig"}**). Regarding the three analyzed hippocampal areas (i.e., the DG, CA1, and CA3), increased numbers of Iba1-ir cells were found in the DG and CA1 areas of both the acute and repeated cocaine groups (^\*^*P* \< 0.05). In contrast, no changes and a decrease (^\*^*P* \< 0.05) in the number of Iba1-ir cells were detected in the CA3 areas of the acute and repeated cocaine groups, respectively. Notably, the increase in the number of Iba1-ir cells was significantly greater in the hippocampus of the acute cocaine group than in the repeated cocaine group (^\$\$\$^*P* \< 0.001). Specifically, this difference in Iba1-ir cell numbers between the acute and repeated cocaine groups was observed in the CA1 and CA3 fields (^\$^*P* \< 0.05 and ^\$\$\$^*P* \< 0.001, respectively) and not in the DG (**Figures [7B,J--L](#F7){ref-type="fig"}**). Greater numbers of Iba1-ir cells were also observed in the hippocampi of the AM630 and Rimonabant-treated rats compared to the vehicle-treated rats (^\*\*\*^*P* \< 0.001; **Figures [7B,M,O](#F7){ref-type="fig"}**). The levels of significance of these effects varied across the three analyzed hippocampal regions (i.e., the DG, CA1, and CA3). Notably, AM630 and Rimonabant failed to affect the numbers of Iba1-ir cells in the hippocampi (or the specific hippocampal regions) in the repeated cocaine-treated rats (**Figures [7B,N,P](#F7){ref-type="fig"}**).

DISCUSSION
==========

The present study contributes three main new findings to the understanding of the role of cell proliferation in cocaine addiction. First, pharmacological blockade of either CB~1~ or CB~2~ cannabinoid receptors during the acquisition of behavioral sensitization in a specific context affects hippocampal-dependent conditioned locomotion but not the expression of sensitized responses to cocaine. Second, the absence of cocaine-induced conditioned locomotion in the cannabinoid antagonist-treated animals was associated with enhancements of cell proliferation in the hippocampus. Third, cocaine-induced an activation of the glial compartment that was partially counteracted by the blockade of either CB~1~ or CB~2~ receptors. In the SVZ, repeated cocaine decreased cell proliferation, and the blockade of either of the cannabinoid receptors partially counteracted this effect. Overall, the present study demonstrated that the endogenous cannabinoid system participates in the effects of cocaine on both brain cell proliferation and the emergence of conditioned responses associated with the administration of conditioned responses associated with the administration of cocaine (**Table [1](#T1){ref-type="table"}**).

###### 

Summary of the main effects of acute and repeated administration and co-administration of cocaine with Rimonabant or AM630 on factors related to cell proliferation, apoptosis and gliosis.

                                                    Proliferation (BrdU)   Apoptosis (Caspase 3)   Astrogliosis (GFAP)   Microgliosis (Iba1)                 
  ------------------------------------------------- ---------------------- ----------------------- --------------------- --------------------- ---- --- ---- ----
  Acute cocaine^[1](#fn01){ref-type="fn"}^          ↓                      ↓                       ns                    ↑                     ↑    ↑   ns   ↑
  Repeated cocaine^[1](#fn01){ref-type="fn"}^       ↓                      ns                      ns                    ↑                     ns   ↑   ns   ↑
  AM630^[1](#fn01){ref-type="fn"}^                  ↓                      ↑                       ns                    ↑                     ns   ↑   ns   ↑
  Rimonabant^[1](#fn01){ref-type="fn"}^             ↓                      ↑                       ↓                     ns                    ns   ↑   ns   ↑
  Cocaine + AM630^[2](#fn02){ref-type="fn"}^        ↑                      ↑                       ns                    ↓                     ↓    ↓   ↓    ns
  Cocaine + Rimonabant^[2](#fn02){ref-type="fn"}^   ↑                      ↑                       ↓                     ↓                     ns   ↓   ↓    ns

Effects of acute cocaine, repeated cocaine, AM630 and Rimonabant versus vehicle.

Effects of repeated cocaine + AM630 or Rimonabant versus repeated cocaine.

Conditioned locomotion is a conditioned behavioral response in which hippocampus-dependent contextual memories of previous cocaine exposure boost behavioral arousal and locomotion. In a recent study, we demonstrated this link in a mouse model with disruptions of glutamatergic transmission and deficits in neurogenesis in the hippocampus; in the Málaga variant of the lysophosphatidic acid type 1 receptor knockout mice ([@B29]; [@B5]), hippocampal alterations are associated with profound disruptions of cocaine-induced conditioned locomotion responses ([@B5]) but not cocaine-induced sensitization. Although in the present work we do not provide direct evidence linking the cell proliferation responses activated by cannabinoid receptor blockade to the disappearance of conditioned locomotion, there is growing evidence linking the restoration of hippocampal neurogenesis to extinction and protection against cocaine seeking behaviors ([@B35], [@B34]; [@B26]). Our results indicate that the impairments of cell proliferation induced by cocaine are counteracted by pharmacological blockade of either the CB~1~ or CB~2~ cannabinoid receptor, which corroborates the previous suggestion that cell proliferation events in the adult neurogenic niche are under the control of both cannabinoid receptors ([@B1]; [@B10]). In fact, dopamine D2/D3 receptor activation has been linked to both, enhancement of anandamide release and reduction of neurogenesis, suggesting a convergent mechanism for dopamine and anandamide in the inhibition of cell proliferation ([@B40]; [@B8]). Although the effects on cell proliferation were more pronounced after cannabinoid CB~1~ receptor blockade, the well-known actions of CB~1~ blockade on anxiety precludes the use of cannabinoid CB~1~ receptor blockers as a restorative therapy in addiction ([@B33]). Indeed, cannabinoid CB~2~ receptor-mediated responses are much more interesting, and there is evidence that genetic manipulation or pharmacological blockade of cannabinoid CB~2~ receptors modulates cocaine-addiction related behaviors ([@B45]; [@B4]). Based on the present results, we speculate that the positive outcomes of those studies also relied on the restoration of neurogenesis in the hippocampus. Additionally, increased cell proliferation in the hippocampus due to pharmacological blockade of cannabinoid receptors in the cocaine-treated rats was associated with decreases in mortality (see the cleaved-caspase expression results), which suggests that these new cells had the opportunity to mature and become fully functional. In any case, further studies to address the destinies (in terms of phenotype and circuit integration) and roles of these new hippocampal cells in the contextual memories associated with cocaine administration are underway.

An interesting aspect of the present results is the dissociation between the effects of cannabinoid receptor blockade on conditioned locomotion and sensitization of the responses to cocaine. This dissociation supports the existence of multiple independent circuits that differentially adapt to the effects of cocaine and the differential contributions of endocannabinoids to these circuits. While cannabinoid regulation of the hippocampal memories associated with cocaine has been implicated in the acquisition of cocaine self-administration and cue-induced relapse ([@B9]), the actions of cannabinoid receptors on sensitization to psychostimulants are controversial. There are reports that indicate a clear role of cannabinoid receptors in the acquisition of this behavioral adaptation to repeated cocaine exposure ([@B14]; [@B44]; [@B31]). However, there are also reports that indicate that the genetic deletion of cannabinoid receptors has no influence on this effect of cocaine ([@B25]; [@B44]). Under our experimental conditions, we found that blockade of the cannabinoid CB~1~ receptor delayed the acquisition of sensitization, but after the animals were challenged with a 6-day period of incubation, the response to cocaine was equally increased. This finding indicates that, although interference with the molecular mechanisms controlled by the CB~1~ receptors in the basal ganglia may interfere with the molecular adaptations associated with repeated cocaine exposure, the sensitized response is ultimately acquired and expressed. Moreover, the findings that cell proliferation in the adjacent SVZ is increased by either CB~1~ or CB~2~ blockade suggests that this response is apparently not related to the sensitization process, which primarily relies on dopamine-glutamate interactions in dopaminoceptive medium-spiny neurons in the basal ganglia ([@B6]).

Finally, the ability of cannabinoid CB~1~ receptor blockade to attenuate the glial response to cocaine is an interesting finding of this study. As has been previously described in the medial prefrontal cortex, both the astroglial and microglial compartments were activated after cocaine exposure ([@B28]). Pharmacological blockade of either cannabinoid CB~1~ or CB~2~ receptors attenuated this reactivity and normalized the glial compartments of the animals that received cocaine. Both glial cell types are relevant to the induction of plastic changes in the hippocampus and striatum, and the effects of the functions of these cells on cocaine-associated behaviors demand further investigation. However, preliminary studies have clearly indicated that astrocytes, through the regulation of glutamate dynamics, contribute to cocaine addiction ([@B28]; [@B26]). In fact, cocaine administration is capable of regulating the expression and activity of two of the main enzymes that regulate synthesis of glutamate and are expressed in astrocytes, the K and L glutaminase isoforms ([@B5]). In contrast, the inflammatory pattern of microglia reactivity after cocaine administration suggests that cannabinoid receptors might regulate this response, which is thought to contribute to the plastic changes that result from cocaine exposure.

Overall, the results of the present study suggest that the endogenous cannabinoid system is a key regulatory element of the plastic changes that are associated with cocaine-induced behavioral responses in the rat. This modulatory role is mediated by the signaling processes that are activated by both cannabinoid CB~1~ and CB~2~ receptors. The neuroadaptations to cocaine that are under cannabinoid control include cell proliferation, cell survival and glial activation. Given the clinical withdrawal of cannabinoid CB~1~ antagonists, our results suggest that cannabinoid CB~2~ receptor antagonists are suitable targets for the development of therapies for cocaine addiction.
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BrdU

:   5-bromo-2′-deoxyuridine

CA1/3

:   field 1/3 of the Cornu Ammonis

DG

:   dentate gyrus

gcl

:   granular cell layer

ml

:   molecular layer

pcl

:   polymorphic cell layer

SGZ

:   subgranular zone of dentate gyrus

SL-M

:   stratum lacunosum-moleculare

SO

:   stratum oriens

SP

:   stratum pyramidale

SR

:   stratum radiatum

SVZ

:   subventricular zone of the lateral ventricles.
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